Form 4: Heron Therapeutics Exec Converts RSUs

Heron Therapeutics' EVP, Chief Development Officer, William P. Forbes, converted 11,695 restricted stock units into common stock.

Summary

• William P. Forbes, Executive Vice President and Chief Development Officer at Heron Therapeutics, Inc. (HRTX), completed a transaction on July 31, 2025.
• The transaction involved the conversion of 11,695 Restricted Stock Units (RSUs) into an equal number of common shares.
• Following this conversion, Forbes beneficially owns 150,635 shares of common stock.
• Additionally, Forbes continues to beneficially own 163,721 Restricted Stock Units.
• The Restricted Stock Units vest in 16 equal installments, with the vesting schedule commencing one quarter after January 31, 2025.

Sentiment

Score: 7

Explanation: The filing reports a routine conversion of restricted stock units into common stock by a key executive, indicating the vesting of equity compensation and continued alignment of executive interests with shareholders.

Positives

• The conversion of restricted stock units into common stock represents the vesting of equity compensation, a standard component of executive remuneration.
• The executive's continued beneficial ownership of a substantial number of common shares (150,635) and remaining RSUs (163,721) aligns their financial interests with those of shareholders.

Future Outlook

NA

Industry Context

This Form 4 details a routine equity compensation event for an executive, common across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors where long-term incentives like Restricted Stock Units are prevalent.

Comparison to Industry Standards

• The conversion of Restricted Stock Units (RSUs) into common stock is a standard practice for executive compensation across various industries, including pharmaceuticals and biotechnology. This transaction aligns with typical equity vesting schedules designed to retain talent and align executive interests with shareholder value over time.

Related Party Transactions

• The transaction involves an executive's equity compensation, which is a standard form of related party dealing between the company and its management.

Stakeholder Impact

• Shareholders: The conversion of RSUs into common stock slightly increases the outstanding share count, but it also demonstrates an executive's continued equity stake, aligning their interests with shareholder value.
• Employees: This transaction highlights the company's executive compensation structure, which may influence employee perception of equity incentives.

Next Steps

• Continued vesting of the remaining 163,721 Restricted Stock Units in 16 equal installments, starting one quarter after January 31, 2025.

Key Dates

Recommendation

The filing details a routine executive equity compensation event (RSU conversion) and does not provide new information that would significantly alter the investment thesis for Heron Therapeutics. It confirms an executive's continued equity stake, which is generally positive for alignment, but does not warrant a change in investment recommendation based solely on this filing.

Keywords

Heron Therapeutics, HRTX, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Executive Compensation, William P. Forbes